Drug Patents Expiring in 2036
1. Drug name - AIRDUO DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9782550
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
|
US9782551
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
|
US10918816
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Jun, 2036
(13 years from now) | |
| US10569034 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Treatment: NA
Dosage: POWDER;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.113MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.232MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
2. Drug name - ARMONAIR DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9782550
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
|
US9782551
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
|
US10918816
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Jun, 2036
(13 years from now) | |
| US10569034 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH | POWDER;INHALATION | Discontinued |
| 0.113MG/INH | POWDER;INHALATION | Discontinued |
| 0.232MG/INH | POWDER;INHALATION | Discontinued |
| 0.03MG/INH | POWDER;INHALATION | Discontinued |
3. Drug name - AUSTEDO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
|
US10959996
(Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(13 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Treatment: A method of treating huntington's chorea
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 6MG | TABLET;ORAL | Prescription |
| 9MG | TABLET;ORAL | Prescription |
| 12MG | TABLET;ORAL | Prescription |
4. Drug name - BALVERSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(13 years from now) | |
Drugs and Companies using ERDAFITINIB ingredient
Treatment: Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | TABLET;ORAL | Prescription |
| 4MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
5. Drug name - BAQSIMI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10213487 | ELI LILLY AND CO | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(13 years from now) | |
Drugs and Companies using GLUCAGON ingredient
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | POWDER;NASAL | Prescription |
6. Drug name - BIKTARVY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548846 | GILEAD SCIENCES INC | Therapeutic compositions for treatment of human immunodeficiency virus |
Nov, 2036
(14 years from now) | |
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 30MG BASE;120MG;EQ 15MG BASE | TABLET;ORAL | Prescription |
| EQ 50MG BASE;200MG;EQ 25MG BASE | TABLET;ORAL | Prescription |
7. Drug name - BRILINTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(13 years from now) | |
Drugs and Companies using TICAGRELOR ingredient
Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 60MG | TABLET;ORAL | Prescription |
| 90MG | TABLET;ORAL | Prescription |
8. Drug name - CALQUENCE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) | |
| CN108349978A | ASTRAZENECA | (S) -4-(8-Amino - -3-(1 - (But - -2 - Alkyne Acyl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin - -1 - Yl) - N - (Pyridine - -2 - Yl) Benzamide In Solid Form And Preparation |
Jul, 2036
(13 years from now) | |
| CN108349978B | ASTRAZENECA | Solid Forms And Formulations Of (S) -4-(8-Amino - -3-(1 - (But - -2 - Yn-Yl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin-1-Yl) -N-(Pyridine-2-Yl) Benzamide |
Jul, 2036
(13 years from now) | |
| EP3317281A1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| EP3317281B1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| EP3613745A1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| EP3613745B1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) | |
Drugs and Companies using ACALABRUTINIB ingredient
Treatment: Treatment of adult patients with small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
9. Drug name - CAROSPIR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10624906 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(14 years from now) | |
| US10660907 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(14 years from now) | |
| US10888570 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(14 years from now) | |
| US10493083 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(14 years from now) | |
| US9757394 | CMP DEV LLC | Spironolactone aqueous formulations |
Oct, 2036
(14 years from now) | |
Drugs and Companies using SPIRONOLACTONE ingredient
Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure
Dosage: SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 25MG/5ML | SUSPENSION;ORAL | Prescription |
10. Drug name - COTELLIC
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(13 years from now) | |
| US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(13 years from now) | |
| CN108135854A | GENENTECH INC | Drug-Containing Immediate Release Tablets And A Method Of Forming A Tablet |
Jun, 2036
(13 years from now) | |
| CN108135854B | GENENTECH INC | Immediate Release Tablet Containing Medicine And Method For Forming Tablet |
Jun, 2036
(13 years from now) | |
| EP3316867B1 | GENENTECH INC | Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets |
Jun, 2036
(13 years from now) | |
| EP3316867A1 | GENENTECH INC | Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets |
Jun, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET;ORAL | Prescription |
11. Drug name - CYCLOPHOSPHAMIDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10993952 | INGENUS PHARMS LLC | Stable ready to use cyclophosphamide liquid formulations |
Feb, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 1GM/5ML (200MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 2GM/10ML (200MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 500MG/2.5ML (200MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
12. Drug name - CYSVIEW KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10556010 | PHOTOCURE ASA | Neoadjuvant therapy for bladder cancer |
Dec, 2036
(14 years from now) | |
Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient
Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy
Dosage: FOR SOLUTION;INTRAVESICAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/VIAL | FOR SOLUTION;INTRAVESICAL | Prescription |
13. Drug name - DAURISMO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) | |
| EP3666768B1 | PFIZER | Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1) |
Apr, 2036
(13 years from now) | |
| EP3286176A1 | PFIZER | Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate |
Apr, 2036
(13 years from now) | |
| EP3666768A1 | PFIZER | Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1) |
Apr, 2036
(13 years from now) | |
| EP3286176B1 | PFIZER | Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate |
Apr, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) | |
Drugs and Companies using GLASDEGIB MALEATE ingredient
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 25MG BASE | TABLET;ORAL | Prescription |
| EQ 100MG BASE | TABLET;ORAL | Prescription |
14. Drug name - DELSTRIGO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842751 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(14 years from now) | |
| US10603282 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(14 years from now) | |
Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG;300MG;300MG | TABLET;ORAL | Prescription |
15. Drug name - DEXMEDETOMIDINE HYDROCHLORIDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717796 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) | |
| US9649296 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) | |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG BASE/10ML (EQ 100MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
16. Drug name - DUOBRII
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10251895 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(13 years from now) | |
| US10426787 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(13 years from now) | |
Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.01%;0.045% | LOTION;TOPICAL | Prescription |
17. Drug name - ELYXYB
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376527 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
| US9572819 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
| US9795620 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
| US9949990 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
| US10799517 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
| US10722456 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
Drugs and Companies using CELECOXIB ingredient
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 25MG/ML | SOLUTION;ORAL | Prescription |
18. Drug name - ENTRESTO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11058667 | NOVARTIS PHARMS CORP | Sacubitril-valsartan dosage regimen for treating heart failure |
May, 2036
(13 years from now) | |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Treatment: Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 24MG;26MG | TABLET;ORAL | Prescription |
| 49MG;51MG | TABLET;ORAL | Prescription |
| 97MG;103MG | TABLET;ORAL | Prescription |
19. Drug name - EPANED
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9669008 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US10154987 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US9808442 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US10039745 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US11173141 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US11141405 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US11040023 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US10772868 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
| US10786482 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
Drugs and Companies using ENALAPRIL MALEATE ingredient
Treatment: Treatment of hypertension; method of treating left ventricular dysfunction; method of treating hypertension; method of treatment of heart failure; treatment of heart failure; Method of treatment of heart failure; treatment of heart failure; method of treating hypertension; method of treating left ventricular dysfunction; treatment of hypertension
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG/ML | SOLUTION;ORAL | Prescription |
20. Drug name - ESOMEPRAZOLE MAGNESIUM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(14 years from now) | |
| US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(14 years from now) | |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | Discontinued |
21. Drug name - EXEM FOAM KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9849199 | GISKIT | Composition and method for medical imaging of body cavities |
Feb, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 10ML | FOAM;INTRAUTERINE | Prescription |
22. Drug name - EZALLOR SPRINKLE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10413543 | SUN PHARM | Stable multiparticulate pharmaceutical composition of rosuvastatin |
Feb, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | CAPSULE;ORAL | Prescription |
| EQ 10MG BASE | CAPSULE;ORAL | Prescription |
| EQ 20MG BASE | CAPSULE;ORAL | Prescription |
| EQ 40MG BASE | CAPSULE;ORAL | Prescription |
23. Drug name - FINTEPLA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10947183 | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(14 years from now) | |
| CN108883399A | ZOGENIX INC | Fenfluramine Composition And Preparation Method Thereof |
Dec, 2036
(14 years from now) | |
| CN108883399B | ZOGENIX INC | Faffluramine Composition And Preparation Method Thereof |
Dec, 2036
(14 years from now) | |
| EP3393655A4 | ZOGENIX INC | Fenfluramine Compositions And Methods Of Preparing The Same |
Dec, 2036
(14 years from now) | |
| EP3393655A1 | ZOGENIX INC | Fenfluramine Compositions And Methods Of Preparing The Same |
Dec, 2036
(14 years from now) | |
| EP3393655B1 | ZOGENIX INC | Fenfluramine Compositions And Methods Of Preparing The Same |
Dec, 2036
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.2MG BASE/ML | SOLUTION;ORAL | Prescription |
24. Drug name - FYARRO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10705070 | AADI | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
Mar, 2036
(13 years from now) | |
| US10973806 | AADI | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
Jun, 2036
(13 years from now) | |
Drugs and Companies using SIROLIMUS ingredient
Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/VIAL | POWDER;INTRAVENOUS | Prescription |
25. Drug name - GAVRETO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(14 years from now) | |
| CN108473468B | GENENTECH INC | Inhibitors Of Ret |
Nov, 2036
(14 years from now) | |
| CN108473468A | GENENTECH INC | Inhibitors Of Ret |
Nov, 2036
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
26. Drug name - GENOSYL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10213572 | VERO BIOTECH | Nitrogen dioxide storage cassette |
Feb, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 800PPM | GAS;INHALATION | Prescription |
27. Drug name - GLOPERBA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9907751 | ROMEG | Composition and method of use of colchicine oral liquid |
Nov, 2036
(14 years from now) | |
| US10383820 | ROMEG | Colchicine drug-to-drug interactions |
Nov, 2036
(14 years from now) | |
| US10383821 | ROMEG | Colchicine drug-to-drug interactions |
Nov, 2036
(14 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.6MG/5ML | SOLUTION;ORAL | Prescription |
28. Drug name - GVOKE HYPOPEN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649364 | XERIS | Methods for producing stable therapeutic formulations in aprotic polar solvents |
Apr, 2036
(13 years from now) | |
Drugs and Companies using GLUCAGON ingredient
Treatment: Treatment of severe hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 0.5MG/0.1ML (0.5MG/0.1ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 1MG/0.2ML (1MG/0.2ML) | SOLUTION;SUBCUTANEOUS | Prescription |
29. Drug name - IBRANCE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11065250 | PFIZER | Solid dosage forms of palbociclib |
May, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 75MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
| 125MG | TABLET;ORAL | Prescription |
30. Drug name - IMBRUVICA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10828259 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10010507 | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10213386 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US9655857 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 140MG | TABLET;ORAL | Prescription |
| 280MG | TABLET;ORAL | Prescription |
| 420MG | TABLET;ORAL | Prescription |
| 560MG | TABLET;ORAL | Prescription |
31. Drug name - INGREZZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(14 years from now) | |
| US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(14 years from now) | |
| US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(14 years from now) | |
| US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(14 years from now) | |
| US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(14 years from now) | |
| US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(14 years from now) | |
| US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(14 years from now) | |
| EP3368534A1 | NEUROCRINE | Valbenazine Ditosylate And Polymorphs Thereof |
Oct, 2036
(14 years from now) | |
| EP3368534B1 | NEUROCRINE | Valbenazine Ditosylate And Polymorphs Thereof |
Oct, 2036
(14 years from now) | |
| EP3394057B1 | NEUROCRINE | Synthetic Method For Preparation Of (S)-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1,-A]Lsoquinolin-2-Yl 2-Amino-3-Methylbutanoate Di(4-Methylbenzenesulfonate) |
Dec, 2036
(14 years from now) | |
| EP3394057A1 | NEUROCRINE | Synthetic Method For Preparation Of (S)-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1,-A]Lsoquinolin-2-Yl 2-Amino-3-Methylbutanoate Di(4-Methylbenzenesulfonate) |
Dec, 2036
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | CAPSULE;ORAL | Prescription |
| EQ 60MG BASE | CAPSULE;ORAL | Prescription |
| EQ 80MG BASE | CAPSULE;ORAL | Prescription |
32. Drug name - INLYTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Nov, 2036
(14 years from now) | |
Drugs and Companies using AXITINIB ingredient
Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
33. Drug name - INOMAX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9770570 | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(13 years from now) | |
|
US9770570
(Pediatric) | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(14 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Treatment: A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide
Dosage: GAS;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 100PPM | GAS;INHALATION | Discontinued |
| 800PPM | GAS;INHALATION | Prescription |
34. Drug name - INVEGA HAFYERA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(13 years from now) | |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; reinitiation of schizophrenia treatment following a missed dose 4-9 months ago
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
| Strength | Dosage | Availability |
|---|---|---|
| 1.092GM/3.5ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 1.560GM/5ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 273MG/0.875ML (273MG/0.875ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 410MG/1.315ML (311.79MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 546MG/1.75ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 819MG/2.625ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
35. Drug name - KISQALI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 200MG BASE | TABLET;ORAL | Prescription |
36. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) | |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG;EQ 200MG BASE | TABLET;ORAL | Prescription |
37. Drug name - KORLYM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9943526 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(13 years from now) | |
| US10166242 | CORCEPT THERAP | Optimizing mifepristone levels for Cushing's patients |
Apr, 2036
(13 years from now) | |
| US10166243 | CORCEPT THERAP | Optimizing mifepristone levels for cushing'S patients |
Apr, 2036
(13 years from now) | |
| US10660904 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(13 years from now) | |
| US10006924 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent cushing's syndrome |
Aug, 2036
(13 years from now) | |
| US10495650 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(13 years from now) | |
| US9829495 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(13 years from now) | |
Drugs and Companies using MIFEPRISTONE ingredient
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 300MG | TABLET;ORAL | Prescription |
38. Drug name - KYNMOBI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449146 | SUNOVION PHARMS INC | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(13 years from now) | |
| US10959943 | SUNOVION PHARMS INC | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(13 years from now) | |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | FILM;SUBLINGUAL | Prescription |
| 15MG | FILM;SUBLINGUAL | Prescription |
| 20MG | FILM;SUBLINGUAL | Prescription |
| 25MG | FILM;SUBLINGUAL | Prescription |
| 30MG | FILM;SUBLINGUAL | Prescription |
39. Drug name - LANSOPRAZOLE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077055 | DEXCEL PHARMA | Orally disintegrating compositions |
Apr, 2036
(13 years from now) | |
Drugs and Companies using LANSOPRAZOLE ingredient
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | Over the counter |
40. Drug name - LEQVIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(13 years from now) | |
Drugs and Companies using INCLISIRAN SODIUM ingredient
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
41. Drug name - LEVOTHYROXINE SODIUM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11154498 | CUSTOPHARM INC | Stabilized liquid formulation of levothyroxine |
Jul, 2036
(13 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MCG/ML | SOLUTION;INTRAVENOUS | Prescription |
42. Drug name - LEVOTHYROXINE SODIUM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398669 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(14 years from now) | |
| US9782376 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(14 years from now) | |
| US11135190 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(14 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MCG/5ML (20MCG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 200MCG/5ML (40MCG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 500MCG/5ML (100MCG/ML) | SOLUTION;INTRAVENOUS | Prescription |
43. Drug name - LEXETTE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020407 | MAYNE PHARMA | Corticosteroid containing foam compositions and method of manufacture thereof |
Nov, 2036
(14 years from now) | |
| US10857159 | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
Nov, 2036
(14 years from now) | |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.05% | AEROSOL, FOAM;TOPICAL | Prescription |
44. Drug name - LONHALA MAGNAIR KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10688518 | SUNOVION RESP | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
Nov, 2036
(14 years from now) | |
| US10744277 | SUNOVION RESP | Aerosol delivery device and method of operating the aerosol delivery device |
Dec, 2036
(14 years from now) | |
Drugs and Companies using GLYCOPYRROLATE ingredient
Treatment: A method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 25MCG/ML | SOLUTION;INHALATION | Prescription |
45. Drug name - LORBRENA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10420749 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| EP3328867A1 | PFIZER | Crystalline Form Of Lorlatinib Free Base |
Jul, 2036
(13 years from now) | |
| EP3328867B1 | PFIZER | Crystalline Form Of Lorlatinib Free Base |
Jul, 2036
(13 years from now) | |
| EP3328867B9 | PFIZER | Crystalline Form Of Lorlatinib Free Base |
Jul, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020376 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 25MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
46. Drug name - LOTEMAX SM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(14 years from now) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.38% | GEL;OPHTHALMIC | Prescription |
47. Drug name - MAKENA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9844558 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(13 years from now) | |
| US11154562 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(13 years from now) | |
| US10471075 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(13 years from now) | |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 1250MG/5ML (250MG/ML) | SOLUTION;INTRAMUSCULAR | Prescription |
| 250MG/ML (250MG/ML) | SOLUTION;INTRAMUSCULAR | Prescription |
| 275MG/1.1ML (250MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
48. Drug name - MAVYRET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(13 years from now) | |
|
US11246866
(Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 100MG;40MG | TABLET;ORAL | Prescription |
49. Drug name - MINOLIRA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103517 | EPI HLTH | Pharmaceutical compositions for minocycline |
Apr, 2036
(13 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 105MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 135MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
50. Drug name - MYCAPSSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238709 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
| US11052126 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
| US10695397 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
Dosage: CAPSULE, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
51. Drug name - MYRBETRIQ GRANULES
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(13 years from now) | |
|
US10058536
(Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Oct, 2036
(14 years from now) | |
Drugs and Companies using MIRABEGRON ingredient
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 8MG/ML | FOR SUSPENSION, EXTENDED RELEASE;ORAL | Prescription |
52. Drug name - NEXLIZET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(13 years from now) | |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
Treatment: A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 180MG;10MG | TABLET;ORAL | Prescription |
53. Drug name - NUBEQA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
| US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
| EP3250554A1 | BAYER HEALTHCARE | A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form |
Jan, 2036
(13 years from now) | |
| EP3250554B1 | BAYER HEALTHCARE | A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form |
Jan, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
Drugs and Companies using DAROLUTAMIDE ingredient
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 300MG | TABLET;ORAL | Prescription |
54. Drug name - OCALIVA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10758549 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(13 years from now) | |
| US10751349 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(13 years from now) | |
| US10052337 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(13 years from now) | |
Drugs and Companies using OBETICHOLIC ACID ingredient
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as monotherapy in adults unable to tolerate udca
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
55. Drug name - OMEPRAZOLE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(14 years from now) | |
| US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(14 years from now) | |
Drugs and Companies using OMEPRAZOLE ingredient
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | Over the counter |
56. Drug name - ONIVYDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456360 | IPSEN INC | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(14 years from now) | |
| US10993914 | IPSEN INC | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(14 years from now) | |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Treatment: NA
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) | INJECTABLE, LIPOSOMAL;INTRAVENOUS | Prescription |
57. Drug name - ORGOVYX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 120MG | TABLET;ORAL | Prescription |
58. Drug name - ORILISSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537572 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
| US10682351 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
Drugs and Companies using ELAGOLIX SODIUM ingredient
Treatment: Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 150MG BASE | TABLET;ORAL | Prescription |
| EQ 200MG BASE | TABLET;ORAL | Prescription |
59. Drug name - ORTIKOS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10172802 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(13 years from now) | |
| US9707182 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(13 years from now) | |
Drugs and Companies using BUDESONIDE ingredient
Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 6MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 9MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
60. Drug name - OXBRYTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020382 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(14 years from now) | |
Drugs and Companies using VOXELOTOR ingredient
Treatment: Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily
Dosage: TABLET, FOR SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 300MG | TABLET, FOR SUSPENSION;ORAL | Prescription |
61. Drug name - PROAIR DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10569034 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Treatment: NA
Dosage: POWDER, METERED;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.09MG BASE/INH | POWDER, METERED;INHALATION | Prescription |
62. Drug name - PROCYSBI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10143665 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
| US10905662 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
| US10548859 | HORIZON PHARMA USA | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
| US10328037 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: GRANULE, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 75MG BASE/PACKET | GRANULE, DELAYED RELEASE;ORAL | Prescription |
| EQ 300MG BASE/PACKET | GRANULE, DELAYED RELEASE;ORAL | Prescription |
63. Drug name - PROCYSBI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10143665 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
| US10328037 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
| US10548859 | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
| US10905662 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: CAPSULE, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 25MG BASE | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
| EQ 75MG BASE | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
64. Drug name - RINVOQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10981923 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US9951080 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US11186584 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10995095 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10597400 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10730883 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US9963459 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10981924 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10519164 | ABBVIE INC | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10344036 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US11198697 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10550126 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
Drugs and Companies using UPADACITINIB ingredient
Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 30MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
65. Drug name - TASCENSO ODT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10925829 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(13 years from now) | |
| US10555902 | HANDA | Stable fingolimod dosage forms |
Jan, 2036
(13 years from now) | |
| US9925138 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(13 years from now) | |
Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient
Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.25MG BASE | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
66. Drug name - TURALIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10730876 | DAIICHI SANKYO INC | Synthesis of a compound that modulates kinases |
May, 2036
(13 years from now) | |
| US9802932 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) | |
| CN107548394B | DAIICHI SANKYO INC | A Solid Form Of The Compound For Modulating Kinase |
May, 2036
(13 years from now) | |
| CN107548394A | DAIICHI SANKYO INC | Solid Forms Of The Kinase Modulating Compound |
May, 2036
(13 years from now) | |
| EP3581573A1 | DAIICHI SANKYO INC | Synthesis Of A Compound That Modulates Kinases |
May, 2036
(13 years from now) | |
| EP3292122B1 | DAIICHI SANKYO INC | Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases |
May, 2036
(13 years from now) | |
| EP3292123B1 | DAIICHI SANKYO INC | Solid Forms Of A Compound Modulating Kinases |
May, 2036
(13 years from now) | |
| EP3581573B1 | DAIICHI SANKYO INC | Synthesis Of A Compound That Modulates Kinases |
May, 2036
(13 years from now) | |
| EP3292123A1 | DAIICHI SANKYO INC | Solid Forms Of A Compound Modulating Kinases |
May, 2036
(13 years from now) | |
| EP3292122A1 | DAIICHI SANKYO INC | Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases |
May, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10189833 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) | |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 200MG BASE | CAPSULE;ORAL | Prescription |
67. Drug name - UPTRAVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(14 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(14 years from now) | |
Drugs and Companies using SELEXIPAG ingredient
Treatment: Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.2MG | TABLET;ORAL | Prescription |
| 0.4MG | TABLET;ORAL | Prescription |
| 0.6MG | TABLET;ORAL | Prescription |
| 0.8MG | TABLET;ORAL | Prescription |
| 1MG | TABLET;ORAL | Prescription |
| 1.2MG | TABLET;ORAL | Prescription |
| 1.4MG | TABLET;ORAL | Prescription |
| 1.6MG | TABLET;ORAL | Prescription |
68. Drug name - VEKLURY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
| US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
Drugs and Companies using REMDESIVIR ingredient
Treatment: Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg)
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/VIAL | POWDER;INTRAVENOUS | Prescription |
| 100MG/20ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
69. Drug name - VITRAKVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10799505 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 25MG BASE | CAPSULE;ORAL | Prescription |
| EQ 100MG BASE | CAPSULE;ORAL | Prescription |
70. Drug name - VITRAKVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10799505 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE/ML | SOLUTION;ORAL | Prescription |
71. Drug name - VOXZOGO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
Drugs and Companies using VOSORITIDE ingredient
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 0.4MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
| 0.56MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
| 1.2MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
72. Drug name - XACIATO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129896 | DARE | Topical formulations and treatments |
Sep, 2036
(13 years from now) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation
Dosage: GEL;VAGINAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2% BASE | GEL;VAGINAL | Prescription |
73. Drug name - XOFLUZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
| CN113004304B | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN112940010B | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN112940010A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN113004304A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| IN346800B | GENENTECH INC | Substituted Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| IN201747041390A | GENENTECH INC | Substituted Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| EP3428170A1 | GENENTECH INC | Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| EP3428170B1 | GENENTECH INC | Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
Treatment: Method for post-exposure prophylaxis of influenza; method for treating influenza
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
| 80MG | TABLET;ORAL | Prescription |
74. Drug name - XOSPATA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | TABLET;ORAL | Prescription |
75. Drug name - XTAMPZA ER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646485 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
| US9968598 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
| US9737530 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
| US10188644 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
Drugs and Companies using OXYCODONE ingredient
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 9MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 13.5MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 18MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 27MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 36MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
76. Drug name - XYOSTED (AUTOINJECTOR)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9950125 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Sep, 2036
(13 years from now) | |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/0.5ML (50MG/0.5ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 75MG/0.5ML (75MG/0.5ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 100MG/0.5ML (100MG/0.5ML) | SOLUTION;SUBCUTANEOUS | Prescription |
77. Drug name - ZEMBRACE SYMTOUCH
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537554 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(13 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | SOLUTION;SUBCUTANEOUS | Prescription |
78. Drug name - ZURAGARD
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9844654 | ZUREX PHARMA | Medical skin applicator apparatus |
Apr, 2036
(13 years from now) | |
Drugs and Companies using ISOPROPYL ALCOHOL ingredient
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SOLUTION;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 70% | SOLUTION;TOPICAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.